$NBIX
NEUROCRINE BIOSCIENCES INC

2012 Q1 Form 10-Q Financial Statement

#000119312512204755 Filed on May 02, 2012

View on sec.gov

Income Statement

Concept 2012 Q1 2011 Q1
Revenue $11.27M $12.51M
YoY Change -9.95% 1464.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.700M $3.200M
YoY Change 15.63% 0.0%
% of Gross Profit
Research & Development $9.388M $7.317M
YoY Change 28.3% -3.72%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $13.06M $10.57M
YoY Change 23.51% -2.1%
Operating Profit -$1.792M $1.939M
YoY Change -192.42%
Interest Expense $100.0K $100.0K
YoY Change 0.0% -85.71%
% of Operating Profit 5.16%
Other Income/Expense, Net $906.0K $943.0K
YoY Change -3.92% 34.71%
Pretax Income -$900.0K $2.900M
YoY Change -131.03% -133.72%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$886.0K $2.882M
YoY Change -130.74% -133.51%
Net Earnings / Revenue -7.86% 23.03%
Basic Earnings Per Share -$0.01 $0.05
Diluted Earnings Per Share -$0.01 $0.05
COMMON SHARES
Basic Shares Outstanding 63.41M shares 54.98M shares
Diluted Shares Outstanding 63.41M shares 56.11M shares

Balance Sheet

Concept 2012 Q1 2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.1M $121.6M
YoY Change 48.93% 83.69%
Cash & Equivalents $76.94M $24.39M
Short-Term Investments $104.1M $97.20M
Other Short-Term Assets $2.079M $1.700M
YoY Change 22.29% -19.05%
Inventory
Prepaid Expenses
Receivables $1.800M $3.300M
Other Receivables $0.00 $0.00
Total Short-Term Assets $185.0M $126.6M
YoY Change 46.11% 85.36%
LONG-TERM ASSETS
Property, Plant & Equipment $1.837M $1.300M
YoY Change 41.31% -40.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.00M $0.00
YoY Change -100.0%
Other Assets $4.300M $6.100M
YoY Change -29.51% -3.17%
Total Long-Term Assets $25.17M $7.400M
YoY Change 240.09% -36.21%
TOTAL ASSETS
Total Short-Term Assets $185.0M $126.6M
Total Long-Term Assets $25.17M $7.400M
Total Assets $210.1M $134.0M
YoY Change 56.82% 67.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $596.0K $500.0K
YoY Change 19.2% 0.0%
Accrued Expenses $6.967M $5.900M
YoY Change 18.08% -7.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.63M $49.00M
YoY Change -25.24% 163.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $124.0K $62.00M
YoY Change -99.8% 39.33%
Total Long-Term Liabilities $124.0K $62.00M
YoY Change -99.8% 39.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.63M $49.00M
Total Long-Term Liabilities $124.0K $62.00M
Total Liabilities $66.31M $111.0M
YoY Change -40.26% 75.63%
SHAREHOLDERS EQUITY
Retained Earnings -$725.6M
YoY Change
Common Stock $66.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $143.8M $23.00M
YoY Change
Total Liabilities & Shareholders Equity $210.1M $134.0M
YoY Change 56.82% 67.71%

Cashflow Statement

Concept 2012 Q1 2011 Q1
OPERATING ACTIVITIES
Net Income -$886.0K $2.882M
YoY Change -130.74% -133.51%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$11.20M -$8.580M
YoY Change 30.58% -29.67%
INVESTING ACTIVITIES
Capital Expenditures $404.0K $20.00K
YoY Change 1920.0%
Acquisitions
YoY Change
Other Investing Activities -$44.80M -$21.10M
YoY Change 112.32% -470.18%
Cash From Investing Activities -$45.22M -$21.14M
YoY Change 113.94% -470.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $83.00M $57.00K
YoY Change 145514.04% -99.73%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 83.25M 57.00K
YoY Change 145957.89% -99.73%
NET CHANGE
Cash From Operating Activities -11.20M -8.580M
Cash From Investing Activities -45.22M -21.14M
Cash From Financing Activities 83.25M 57.00K
Net Change In Cash 26.83M -29.66M
YoY Change -190.47% -299.05%
FREE CASH FLOW
Cash From Operating Activities -$11.20M -$8.580M
Capital Expenditures $404.0K $20.00K
Free Cash Flow -$11.61M -$8.600M
YoY Change 34.98% -29.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66307197 shares
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24393000
CY2012Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-127000
CY2012Q1 us-gaap Liabilities Current
LiabilitiesCurrent
36631000
CY2012Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25735000
CY2012Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-725584000
CY2012Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6967000
CY2012Q1 us-gaap Assets
Assets
210141000
CY2012Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2189000
CY2012Q1 us-gaap Common Stock Value
CommonStockValue
66000
CY2012Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1880000
CY2012Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66306302 shares
CY2012Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q1 us-gaap Assets Current
AssetsCurrent
184974000
CY2012Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
124000
CY2012Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
1809000
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76940000
CY2012Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2012Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
869479000
CY2012Q1 us-gaap Long Term Investments
LongTermInvestments
19024000
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
210141000
CY2012Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
143834000
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66306302 shares
CY2012Q1 us-gaap Short Term Investments
ShortTermInvestments
104146000
CY2012Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1837000
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2012Q1 us-gaap Liabilities
Liabilities
66307000
CY2012Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2079000
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1800000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55262734 shares
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
132476000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
125000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
596000
CY2012Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4306000
CY2012Q1 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3064000
CY2012Q1 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
23224000
CY2012Q1 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
269000
CY2012Q1 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2259000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54051000
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-87000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47110000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34242000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-724698000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8451000
CY2011Q4 us-gaap Assets
Assets
138368000
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2919000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1903000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50107000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
784811000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138368000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
60081000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55262734 shares
CY2011Q4 us-gaap Short Term Investments
ShortTermInvestments
78996000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1586000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2011Q4 us-gaap Liabilities
Liabilities
78287000
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1470000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1111000
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4306000
CY2011Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3042000
CY2011Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
24005000
CY2011Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
264000
CY2011Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2328000
CY2011Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
83000
CY2011Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
29453000
CY2011Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21135000
CY2011Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
50649000
CY2011Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2011Q1 us-gaap Revenues
Revenues
12512000
CY2011Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-501000
CY2011Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8580000
CY2011Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2880000
CY2011Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
80000
CY2011Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
99000
CY2011Q1 us-gaap Share Based Compensation
ShareBasedCompensation
712000
CY2011Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2011Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3019000
CY2011Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2000
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
2882000
CY2011Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
943000
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7317000
CY2011Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
CY2011Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2011Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
240000
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1939000
CY2011Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-1241000
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57000
CY2011Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-29658000
CY2011Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54983000 shares
CY2011Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
816000
CY2011Q1 us-gaap Operating Expenses
OperatingExpenses
10573000
CY2011Q1 us-gaap Investment Income Net
InvestmentIncomeNet
119000
CY2011Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2011Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9306000
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3156000
CY2011Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56114000 shares
CY2011Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57000
CY2011Q1 nbix Sponsored Research And Development Revenue
SponsoredResearchAndDevelopmentRevenue
3274000
CY2011Q1 nbix License Fees And Milestones Revenue
LicenseFeesAndMilestonesRevenue
9238000
CY2011Q1 nbix Cease Use Expense
CeaseUseExpense
100000
CY2011Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
736000
CY2011Q1 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
100000
CY2011Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-1214000
CY2012Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2012Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2012Q1 dei Amendment Flag
AmendmentFlag
false
CY2012Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012Q1 dei Document Type
DocumentType
10-Q
CY2012Q1 dei Document Period End Date
DocumentPeriodEndDate
2012-03-31
CY2012Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2012Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11204000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-926000
CY2012Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
25000
CY2012Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2012Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
30548000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45216000
CY2012Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
75385000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2012Q1 us-gaap Revenues
Revenues
11267000
CY2012Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-623000
CY2012Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
80000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1426000
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1999000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
906000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9388000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
404000
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
152000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1792000
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
515000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83253000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26833000
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63409000 shares
CY2012Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
783000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
13059000
CY2012Q1 us-gaap Investment Income Net
InvestmentIncomeNet
121000
CY2012Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-40000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9237000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3671000
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63409000 shares
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83253000
CY2012Q1 nbix Sponsored Research And Development Revenue
SponsoredResearchAndDevelopmentRevenue
2029000
CY2012Q1 nbix License Fees And Milestones Revenue
LicenseFeesAndMilestonesRevenue
9238000
CY2012Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
758000
CY2012Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-64000

Files In Submission

Name View Source Status
0001193125-12-204755-index-headers.html Edgar Link pending
0001193125-12-204755-index.html Edgar Link pending
0001193125-12-204755.txt Edgar Link pending
0001193125-12-204755-xbrl.zip Edgar Link pending
d315181d10q.htm Edgar Link pending
d315181dex311.htm Edgar Link pending
d315181dex312.htm Edgar Link pending
d315181dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
nbix-20120331.xml Edgar Link completed
nbix-20120331.xsd Edgar Link pending
nbix-20120331_cal.xml Edgar Link unprocessable
nbix-20120331_def.xml Edgar Link unprocessable
nbix-20120331_lab.xml Edgar Link unprocessable
nbix-20120331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending